Ameritas Investment Partners Inc. decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 3.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,156 shares of the company’s stock after selling 81 shares during the period. Ameritas Investment Partners Inc.’s holdings in Krystal Biotech were worth $384,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after acquiring an additional 35,632 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after acquiring an additional 383,495 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Krystal Biotech by 5.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after acquiring an additional 30,169 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in shares of Krystal Biotech by 103.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock valued at $31,073,000 after acquiring an additional 127,435 shares during the last quarter. Finally, First Turn Management LLC bought a new position in shares of Krystal Biotech in the 4th quarter valued at about $30,045,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.
Krystal Biotech Trading Down 0.1 %
Shares of Krystal Biotech stock traded down $0.27 on Wednesday, hitting $206.92. 146,193 shares of the company traded hands, compared to its average volume of 380,223. The stock’s 50 day moving average price is $178.73 and its 200-day moving average price is $159.46. Krystal Biotech, Inc. has a 52 week low of $93.95 and a 52 week high of $214.98. The company has a market cap of $5.91 billion, a PE ratio of 110.80 and a beta of 0.84.
Insider Activity
In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Julian S. Gangolli sold 20,000 shares of Krystal Biotech stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.
Analyst Ratings Changes
KRYS has been the subject of a number of analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a research note on Monday, May 6th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and an average price target of $177.63.
Read Our Latest Report on KRYS
Krystal Biotech Profile
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
- Five stocks we like better than Krystal Biotech
- What Are the FAANG Stocks and Are They Good Investments?
- Food Processing Company Stock Gets Fried by Recall: Time to Buy
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Entertainment Stock Offers A Rare and Tempting Entry Opportunity
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Will China’s Interest Rate Cuts Ignite a Rally for This Stock?
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.